Abstracts

The abstract submission site is now open! Submissions are due no later than 11:59 p.m. Pacific time on February 13, 2023.

 

Scientific abstracts that are included in ASTRO's Annual Meeting allow attendees to share important findings with colleagues and interact with leaders in the field. Accepted abstracts represent all aspects of oncology, radiation oncology and radiation therapy for non-oncologic conditions. The scientific program will feature cutting-edge research in all major disease sites, as well as special physics and biology oral abstract sessions.


New to writing research abstracts or just need a refresher?

The ASTRO Academy has a free course available that might answer some of your questions, titled How to Write a Research Abstract for a Meeting. Learn more and register now!


 

Eligibility
  1. Sponsorship or ASTRO membership is not required to submit an abstract.
  2. Abstracts must be received by 11:59 p.m. Pacific time, Monday, February 13, 2023.
  3. All studies in oncology, radiation oncology and radiation therapy for non-oncologic conditions are eligible for submission. This includes basic and translational science, technology-related, health services research, epidemiologic, patient-focused clinical studies and all phases of trials.
  4. An abstract may only be submitted once. Abstracts of clinically-related subjects should be combined into a single abstract. Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
  5. Submit new research. Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.
Abstract Policies on Commercial Interests, Disclosure, Embargo and Copyright
Policy on Studies Sponsored by Commercial Interests
  1. Abstracts may be submitted from ineligible companies (formerly known as commercial interests). Such presentations will be subject to a rigorous peer review to ensure the validity of the research results and conclusions. In addition, abstract content is subject to change after review so that it is not biased toward any proprietary interests.
  2. An ineligible company is defined as any organization that develops, produces, markets, resells or distributes health care goods or services consumed by or used on patients. Any potential conflict will be identified and managed according to ACCME guidelines, and ASTRO’s COI management policies.
  3. The presenting author of an abstract must NOT have a relevant/specific ownership interest, i.e., owner, founder, partner, etc., in the scientific content in the abstract. If a conflict of interest exists, the abstract must be presented by a co-author with no relevant ownership interests.
  4. If the presenting author is employed by an ineligible company, as defined above, an alternate presenter must be named. This applies only to abstracts presented in sessions selected to receive CME, such as oral scientific and Quick Pitch scientific sessions.
  5. ASTRO will exercise all rights in ensuring that abstracts reporting the discovery of scientific research remain in compliance with ACCME standards for offering CME. 

Disclosure Policy
ASTRO is an accredited provider of continuing medical education and adheres to the policies and standards set forth by the Accreditation Council for Continuing Medical Education (ACCME). As such, abstract authors are required to disclose relationships with ineligible companies. The abstract submitter can download this form and use it to collect COI information for all abstract authors.

An ineligible company is defined as “any entity developing, producing, marketing, reselling or distributing health care goods or services consumed by or used on patients.”

To ensure its compliance, ASTRO expects that the content and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias.

We employ several strategies to ensure absence of bias:
  • Presenters are required to provide disclosure of relationships with commercial interests.
  • Presenters are required to provide a balanced view of therapeutic options.
  • All abstracts undergo a rigorous peer review process.
  • Potential conflicts are managed by additional committee review, advance slide review and session audits.

Embargo Policy and ASTRO Press Policy
All abstracts to be presented at the ASTRO Annual Meeting are embargoed until 5:00 p.m. Pacific time on Friday, September 29, 2023. The embargo for all posters at the meeting will also lift at that time. For abstracts selected for oral presentation, information beyond what is included in the abstract, such as updated or additional results, is embargoed until the date and time of scientific presentation or presentation at an ASTRO news briefing, whichever occurs first. The embargo policy applies to all abstracts regardless of whether information is obtained from another source.

Embargo violations by media professionals may result in suspension of credentials at the ASTRO Annual Meeting as well as future meetings and may also impact the ability to receive advance media materials for future meetings. Embargo violations by abstract authors and/or sponsors may result in removal of the abstract from the scientific program. Abstract authors are responsible for notifying financial and other sponsors about this embargo policy.

Questions about the embargo policy may be directed to ASTRO’s media relations team.

The full text of the abstracts selected for oral and poster presentation will be available online at the start of ASTRO’s Annual Meeting. Abstracts also will be published in a supplement of the International Journal of Radiation Oncology • Biology • Physics.


Abstract Copyrights
Once an abstract is submitted to ASTRO, the author (or owner of the IP rights) retains the rights, including the copyright, vis a vis ASTRO upon submission of the abstract for the meeting. However, by submitting the abstract, the owner is granting ASTRO and its affiliates the right and license to publish, use, post, etc. the abstract. You can find more information about the terms of submission here: Elsevier Website Terms & Conditions.
 
Abstract Scoring Criteria

Abstracts will be scored by anonymized peer review based on the following criteria:

  • Does the abstract address an important and novel question?
  • Does the study design permit the question to be answered?
  • Are the endpoints of the study clearly defined?
  • Is there an appropriate use of statistics?
  • Are the methods described in sufficient detail?
  • Are the conclusions supported by the data?

Specific questions for prospective Clinical Trials:

  • What were the scientific hypothesis and primary endpoint?
  • What were the eligibility criteria and study patient characteristics?
  • What statistical model and assumptions were used?
  • What was the toxicity assessment?
  • What were the limitations?
  • Was there a rationale, either clinical or laboratory, underlying the study design?
  • Is it either promising enough to pursue or negative enough that presentation would prevent other investigators from wasting efforts?

Specific questions for retrospective observational studies:

  • What are the scientific hypothesis and outcomes reported?
  • What is the data source and how was follow-up attained?
  • Is the cohort well described and reasonably homogeneous?
  • Have attempts been made to account for biases inherent in retrospective reviews?
  • What statistical methods were used?
  • Are the conclusions appropriate to the study design?
Presenting Author Responsibility
  1. An individual may submit more than one abstract in which they are indicated as the presenting author. However, they may only present one oral presentation. If more than one abstract is selected for oral presentation, an alternate presenter must be assigned, preferably a co-author (this does not apply to poster presentations).
  2. It is the submitter’s responsibility to ensure up-to-date and accurate disclosures are submitted for each co-author on the abstract. ASTRO manages and reports all disclosures as submitted. Potential conflicts with commercial interest for the presenting author and all co-authors must be disclosed at the time of submission.
  3. The presenting author will receive all notifications and email communications related to the accepted abstract(s). The presenting author is responsible for informing all co-authors of acceptance to ASTRO’s Annual Meeting.
  4. ASTRO has developed a policy to handle any violations to the ASTRO Disclosure policy. Any reported violations will be researched and handled according to policy, which can include removal from presenting at future conferences.
  5. Obligation to Register: Acceptance of an abstract obligates the author to present the paper and pay the meeting registration fee. If circumstances prevent attendance, you must notify ASTRO and arrange for an alternate presenter, preferably a co-author. If the presenting author does not register and attend the meeting, your abstract will be removed from the program.
Presentation at Other Meetings
  1. Abstracts should contain new material that has not been presented or published prior to the ASTRO Annual Meeting, October 1-4, 2023. Previously presented abstracts will not be eligible for ASTRO’s official Press Program or Plenary Session.
  2. If the same abstract is accepted for presentation at another major medical meeting (annual meetings of national and international societies with attendance of more than 3,000 participants), or accepted for publication after February 13, 2023, the presenting author must notify ASTRO's Education Team. The Scientific Committee will review and decide on a case-by-case basis if the abstract will remain in the program.
Submission Requirements
  1. Abstract Title: The abstract title should not include results. All titles should be written in title case, and should not include a period at the end.
  2. Abstract Body:
    • Abstracts must be properly formatted and organized into four sections identified by the following bolded headers: Purpose/Objectives, Materials/Methods, Results and Conclusions.
    • Abstracts should include a scientific hypothesis in the Purpose/Objectives section, and implications for research, policy or practice in the Conclusions section, when applicable.
    • The abstract cannot contain illustrations, images or graphs. If the abstract is accepted, presenters may include these items in their on-site presentations.
    • An abstract may contain one small table. 
    • The maximum character limit, including the title and body of the abstract and any text in a table, is 2,600 characters. Spaces are not counted.
    • Institution names should not be included in the title or body of the abstract. Alternative language is “at one institution” or “a multi-institution” study, etc. This does not apply to cooperative research group names. 
  3. Abstract Authors:
    • A maximum of 20 authors’ names may be listed on each abstract. There are no exceptions. 
    • A Conflict of Interest Disclosure form must be submitted for each author. You can collect this information from the authors before you begin the submission using this form.
    • The principal investigator (PI) should be listed as the final author on the abstract.
    • There is no mechanism for listing co-lead authors or co-PI’s.
    • Each author must have made substantial contributions to:
      • conception and design, or analysis and interpretation of data, and
      • drafting the abstract or revising it critically for important intellectual content, and
      • final approval of the version to be submitted/published.
  4. Use of Brand Names and Trade Names: Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract. ASTRO reserves the right to replace proprietary names with generic names.
  5. Track: The most appropriate track and subcategory for the abstract should be selected. Please note that the AM Scientific Committee Chairs have the authority to recategorize any abstract.
  6. Submission Fee: A $75 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Payment must be rendered using a credit card. 
Trials in Progress, Interim Analysis and Database Studies

Trials in Progress
Trials in Progress provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. Trials in Progress will be considered for digital poster only.

Please ensure that the Trial in Progress meets the following criteria before submitting the abstract:

  1. All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion as a Trials in Progress submission.
  2. Trials submitted are ongoing and have not reached pre-specified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.
  3. Enrollment must have already begun or have been completed with no data analysis available by the submission deadline (there are no exceptions to this criterion). It is acceptable if the trial has not enrolled its first patient yet.
  4. Clinical trial registry number is required.

When submitting a Trial in Progress, be sure to check the appropriate box on the Title step of the submission process. Please also select Trial in Progress as the subcategory on the Track step.

Interim Analysis
In general, ASTRO will consider abstracts reporting an interim analysis that is intended to evaluate experimental treatment regimen(s) with respect to efficacy or safety at any time prior to formal completion of a trial on a case-by-case basis.

Abstracts reporting trial process updates, such as accrual, baseline characteristics and non-protocol specific safety information, will be considered for posters only for promotional purposes.

Database Studies
Retrospective registry databases, such as National Cancer Database (NCDB), Surveillance, Epidemiology and End Results (SEER), etc., are valuable resources for patterns of care assessment, and may generate important evidence for comparative effectiveness research.

For comparative effectiveness reports, prioritization will be given to those when the level 1 evidence from randomized trials is obsolete or difficult to obtain. Abstracts should include brief descriptions on statistical methods and justifications, such as the choice of statistical significance level, effect size, methods for confounding adjustment, etc., to facilitate proper interpretations.

Important Deadlines
  1. Abstracts must be received by 11:59 p.m. Pacific time, Monday, February 13, 2023. Abstracts may be edited up until the deadline. Abstracts will be considered ineligible for review if they are incomplete. Abstracts that are unpaid or have payment issues will not be considered. If you do not receive a confirmation receipt, follow up with ASTRO to confirm your “complete” status.
  2. Notifications: The person listed as Presenting Author will be notified via email of the disposition of the abstract by May 8, 2023. Abstract acceptance obligates the author to present the paper at the in-person meeting and pay the meeting registration fee. If circumstances prevent in-person meeting attendance, you must notify ASTRO and arrange for a co-author to present the abstract on your behalf.
  3. Revisions: Please proof your abstract carefully for formatting, spelling and data errors. Pay special attention to the author order and presenting author designation. Review your confirmation email, as this is how the abstract will be published. You can make updates to your abstract until the submission deadline, February 13. After that date, errors can be corrected if sent to ASTRO by July 21, 2023. After this date, we cannot make any corrections. This rule is strictly enforced. Please note: Revisions should not be substantive and should not alter the results or the conclusions of the abstract. Revisions are meant only to correct errors that were made in the initial submission.
  4. Withdrawals: If you choose to withdraw your abstract, please change your decision to “withdraw” in the Speaker Center by July 21, 2023 and notify ASTRO staff via email. After this date, your abstract will be published exactly as it was submitted in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
  5. Submission of an abstract conveys permission to be posted online and printed in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
  6. Late-breaking Abstracts: The late-breaking abstract submission site will open on June 26, 2023, and close July 12, 2023.
Presentation Formats

Plenary Session
Three to five top-rated abstracts are accepted for the Plenary Session and will be offered in an unopposed general assembly. Several of these are usually Late-breaking abstracts. The Plenary Session includes didactic presentations highlighting abstracts of scientific significance deemed to have the highest merit and greatest impact on radiation oncology research and practice. Experts in the field will serve as discussants to place research findings into perspective.

Clinical Trials Session
Up to nine abstracts are accepted for the Clinical Trials Session that will be offered in an unopposed general assembly. Research submitted from significant clinical trials and trials in progress may be selected for this special session. Abstracts reporting trial process updates, such as accrual, baseline characteristics and non-protocol specific safety information, will not be considered for the Clinical Trials Session but instead be considered for Posters only for informational purposes. Previously presented results may be considered if they are deemed relevant by the program planning committee.

Oral Scientific Sessions
Oral abstract sessions provide pedagogic presentations of scientific research. Typically, approximately 350 accepted abstracts are scheduled in 60- and 75-minute sessions. Each presenter is given seven minutes to present his or her paper immediately followed by a three-minute question and answer period. Oral presentations are grouped together by track. Experts in the field (discussants) are chosen to provide comprehensive themed discussions of the findings from selected abstracts in a session.

Quick Pitch Sessions
Quick pitch sessions are 60 minutes long, including more fast-paced presentation of scientific research, allowing extra time for discussion. Each presenter is given 5-minutes to present his or her paper. Thirty minutes of Q&A follows these presentations, moderated by a Discussant. Oral presentations are grouped together by track. Experts in the field (discussants) are chosen to provide comprehensive themed discussions of the findings from selected abstracts in a session.

Poster Q&A Sessions
Back by popular demand, all poster viewing presentations will be displayed as electronic posters! Posters will be presented on large, touchscreen monitors and every poster presenter will be assigned a time to present their poster to an audience. Posters are uploaded with our vendor, MultiLearning, and technical help is provided. Digital posters utilize multimedia to present scientific studies in an engaging way.

Tracks and Subcategories

There are 21 tracks separated by disease site. Abstracts should be submitted in the most appropriate track. Please note that abstracts may be re-categorized by the Track Chairs as deemed appropriate.

To build on the conference theme, Pay It Forward: Partnering With Our Patients, we are seeking abstracts that fit within the 21 tracks and also soliciting abstracts that may cover these areas of interest:

  • Community Partnerships and Engagement: Clinical trials (Inclusive enrollment, diversification, accruals, visibility, community outreach)
  • Patient-centered Technologies
  • Supportive Care Models
  • Engaging Patients, Patient Advocates, Caregivers through Shared decision Making
  • Patient-centered Clinical Trial Design (design, staffing, communication, coordination, access, navigating CT system)

Abstract Tracks and Subcategories

Track Subcategories
Breast Cancer DCIS-Ductal Carcinoma in situ
Early-stage Invasive
Advanced-stage Invasive
Toxicity
Altered Fractionation
Immunotherapy
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Central Nervous System Gliomas (Low Grade, High Grade)
Benign Brain Tumors
Brain Metastasis
Spinal Cord and Spine
Optic Nerve/Ocular Melanoma
CNS Normal Tissue Effects
Immunotherapy/Targeted Therapy
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Miscellaneous/Other
Digital Health Innovation and Informatics Artificial Intelligence
Analytics, Models and Visualization Methods
Bioinformatics
Big Data
Clinical Practice Integration
Machine Learning
Ontologies, Nomenclatures, Standardizations
Omics
Diversity, Equity and Inclusion in Health Care Health Inequities
Health Systems and Access to Care
Workforce and/or Workforce Disparities
Inclusion
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Gastrointestinal Cancer Esophago-gastric
Gastric/small bowel/neuroendocrine
Pancreatic
Hepato-biliary (liver, bile duct, gallbladder)
Colon/Rectum/Anus
Miscellaneous - abdominal
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Genitourinary Cancer Prostate
Bladder
Immunotherapy
Kidney/Adrenal/Ureter
Testis/Penile
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Gynecological Cancer Cervix
Immunotherapy
Uterus/Endometrium
Vulva/Vagina/Ovary
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Head and Neck Cancer Oral cavity
Oropharynx
Nasopharynx
Larynx/Hypopharynx
Nasal cavity/Paranasal sinuses
Salivary gland
Thyroid
Skin Cancer
Orbital/Ocular/Ocular melanoma
Immunotherapy
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Health Services Research/
Global Oncology
Health Services Research Methodology
Comparative Effectiveness
Cost Effectiveness
Decision Making
Health Policy
Global Oncology
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Hematologic Malignancies Hodgkin Lymphoma
Aggressive (B&T cell) Non-Hodgkin Lymphoma
Low-grade Lymphoma
Mycosis Fungoides/Cutaneous T-cell lymphoma
Leukemia
Multiple Myeloma/ Plasmacytoma
Lymphoma Radiation Techniques and Toxicity
Immunotherapy/Cellular Therapy
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Lung Cancer/Thoracic Malignancies Non-small Cell Lung Cancer
Small Cell Lung Cancer
Rare Thoracic Cancers-Thymic Tumors, Mesothelioma
Oligometastasis/Oligoprogression
Immunotherapy
Miscellaneous/Other
Health Care Disparities in the Diagnosis Management and Outcomes of Lung Cancer
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Nonmalignant Disease Cardiac
CNS
Musculoskeletal
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Nursing and Supportive Care Clinical
Patient Education/Shared Decision Making
Supportive Care
Palliative Care Palliative Care - General
Symptom Management
Communication Skills
Prognostication
Treatment Planning/Toxicity
Oligometastases/SBRT
Re-irradiation
Integration with Systemic Therapy/Immunotherapy
Miscellaneous/other 
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Patient Reported Outcomes/
QoL/Survivorship
Patient Reported Outcomes
Quality of Life
Survivorship/Survivor Care
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Patient Safety Quality Assurance
Clinic Workflow & Process
Segmentation Workflow & Process
Peer Review
Incident Learning
IT/Information Technology
Machine Learning in Safety
Automation/Standardization in Safety
Learning from our Errors:  Case Studies from the Field
Miscellaneous/Other
Pediatric Cancer CNS
Immunotherapy
Leukemia/Lymphoma
Neuroblastoma
Retinoblastoma
Sarcoma (soft tissue, bone)
Wilm's tumor
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Professional Development/
Medical Education
History of Radiation Oncology
Medical Education in Radiation Oncology
Academic Productivity
Mental Health and Wellness
Learning Methodologies
Social Media
GME/CME
Professionalism
Medical Ethics
Biology – Radiation and Cancer Biology Normal Tissue Injury, Mutagenesis, Carcinogenesis
DNA Damage Induction, Repair and the Damage Response
Cell Cycle and Tissue Kinetics
Tumor Biology and Signaling Pathways
Radiation Protection-Biodosimetry/Protectors/Mitigators/Treatment
High LET/Radiation and Dose Rate Effects
Translational Research – Radionuclides for Imaging, Therapy and Dosimetry
Translational Research – Experimental Therapeutics and Sensitizers
Translational research – Genomic and Molecular Biomarkers
Immunotherapy and the Immune Response
Special Biology Session – Diversity and Inclusion in Radiobiology
Miscellaneous/Other
Physics – Radiation and Cancer Physics Special Physics Session: Advances in image acquisition, reconstruction and use in RT
Adaptive and automated processes: Offline and online
Delivery: Hardware Technologies and Novel Procedures
Delivery: Treatment Techniques
Delivery: Safety, QA and Efficiency
Planning: Algorithms and Optimization
Imaging for Positioning and Monitoring
Imaging for Planning (Including Auto-segmentation or Functional Imaging)
Planning/Delivery: Motion management
Planning/Delivery: SRS and SBRT
Imaging for Response Assessment
Miscellaneous/Other
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Sarcoma and Cutaneous Tumors Soft Tissue Sarcoma
Bone Sarcoma
Melanoma
Non-melanoma Skin Cancers (including Merkel Cell (non-Head and Neck)
Immunotherapy and Other Systemic Therapy
Trials in Progress/Encore Study/Review-style Abstract (Poster Only)
Late-breaking Abstracts
  1. The late-breaking abstract submission site will open on June 26, 2023, and close July 12, 2023.
  2. A late-breaking abstract is an original research abstract containing important late-breaking research results that were not available prior to the regular abstract submission deadline. The research is limited to highly significant and timely findings and cannot be a revision of an abstract submitted prior to the regular submission deadline. Trials in progress are not eligible to be submitted as late-breaking abstracts.
  3. Late-breaking abstracts must not have been submitted, presented, accepted for presentation or published in any other scientific venue.
  4. A special panel of peer reviewers will review the late-breaking abstracts and the corresponding author will be notified of the abstract status by the early August 2023.
Abstract Awards

Abstract authors can apply for an abstract award during the abstract submission. The deadline to submit an award application is the same as the abstract submission deadline: February 13, 2023.

  • Please see “award criteria” when submitting an online abstract for details of each award. Please note: The author or senior author must be an ASTRO member.
  • If selected, the award winner must present the abstract at the Annual Meeting.
  • Attendance at the meeting is required to obtain the award and honorarium.
  • Please be sure to indicate “resident” or “nurse” in order to be eligible for those awards.
  • Notifications will be emailed to first author by early June.

Steven A. Leibel Memorial Award
Steven A. Leibel, MD, was a former member of the American Board of Radiology (ABR) Board of Trustees and Past President of the ABR. Following his death, a Memorial Fund was established in his memory. For this award, the ABR Foundation will provide two award winners with $2,000 each at the ASTRO Annual Meeting. Winners will be selected by ASTRO leadership and will be selected only from the abstracts designated as Plenary or Clinical Trials presentations. The award winner must be the principal author, ABR board certified or board-eligible, and have completed training in radiation oncology or medical physics no more than 10 years prior to the presentation.

Resident Clinical/Basic Science Research Abstract Awards
This award is designed to promote clinical research by young scientists. The award is granted to the top three resident authors of significant abstracts in biology, clinical practice and physics. The award includes a $1,500 honorarium, a trophy of recognition and complimentary registration to the Annual Meeting.

Basic/Translational Science Abstract Awards
This award is designed to encourage participation by basic and translational scientists. Up to 12 awards will be given to applicants having the top-rated abstracts in biology, clinical practice and physics categories — four awards in each category. The award includes a $1,000 honorarium, certificate of recognition and complimentary registration to the Annual Meeting.

Nurses’ Abstract Award
This award is designed to promote clinical research among radiation oncology nurses. Up to two awards of $1,000 will be presented to the highest rated abstracts with a nursing designation. A certificate of recognition and complimentary registration to the Annual Meeting is included. The candidate must be a first or co-author of an accepted abstract.

International Abstract Award
This grant is designed to foster continuing medical education, assist in career development and help to establish relationships with leading ASTRO members who may serve as scientific mentors to the recipient. One award of $4,000 will be used to support a radiation oncologist in a developing country to attend the ASTRO Annual Meeting and to spend additional time at a comprehensive cancer center within the United States. Complimentary registration to the Annual Meeting is included.

Annual Meeting Travel Awards
To recognize outstanding abstracts submitted by early career scientists, biologists and physicists, up to 15 awards of $1,000 each will be provided to help offset travel expenses to the meeting. Complimentary registration to the Annual Meeting is included. Applications must be submitted during the abstract submission process.

Annual Meeting Resident Recognition Awards

  • Resident Quick Pitch Oral Abstract Recognition Award: This award will recognize the highest rated abstracts submitted by a resident and accepted as an oral presentation in the Quick Pitch scientific sessions. Winners will receive a trophy. The award is granted to one resident author of a significant abstract in each category: biology, clinical practice and physics.
  • Resident Poster Viewing Recognition Award: This award will recognize the highest rated abstracts submitted by residents and accepted as a digital poster. Winners will receive a trophy. Up to nine trophies will be awarded. The award is granted to the top three resident authors of significant abstracts in each category: biology, clinical practice and physics.

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550
www.astro.org

TERMS OF USE & PRIVACY POLICY

Connect With Us: